NILIT
18.4.2024 05:31:30 CEST | Business Wire | Press release
NILIT, the global leader in high-performance Nylon 6.6 fibers for the apparel industry and leader in sustainability, that owns the broadest line of sustainable Nylon 6.6 products, is announcing a new joint venture with Shenma Industry Co., Ltd. (hereinafter referred to as Shenma), a subsidiary of China Pingmei Shenma Group, a global leader in the industrial Nylon 6.6 market and a leading supplier to the automotive industry around the world. This new partnership represents a significant expansion of production capacity within China, also demonstrating NILIT’s ongoing commitment to support the growth of global customers and brands. This expansion is highlighted by multiple investments and cooperation designed to enhance production capabilities and deliver more innovative solutions to the textile industry.
“We are pleased to unveil this new greenfield joint venture in China with Shenma to introduce differentiated state-of-the-art technologies to support the local market,” says Ilan Melamed, NILIT Global General Manager. “This collaboration is set to produce premium specialized products in Fully Drawn Yarns (FDY), known for their outstanding strength and smoothness, and Air Textured Yarns (ATY), known for providing unparalleled softness for the textile market, providing quality and performance, all within a highly competitive cost structure. This partnership will open new opportunities in end uses such as home textiles and the automotive industry where strength, smoothness, and durability are essential.” The joint venture will include a new production site in Pingdingshan, the China Nylon City. The facility will be constructed to meet NILIT’s exacting Total Product Sustainability (TPS) standards for environmentally responsible production and is expected to yield a production capacity of 20,000 tons in the next few years.
This strategic partnership brings together the expertise, resources, and networks of NILIT and Shenma, both renowned enterprises in their respective fields. This joint venture combines NILIT's 50 years of global experience in the production and marketing of high-quality Nylon 6.6 yarns for apparel, and Shenma’s leadership excellence in the Chinese market. “With a shared commitment to excellence and innovation, we are poised to leverage our collective strengths to penetrate new markets and amplify our capabilities across China,” continues Ilan Melamed. The joint venture agreement was signed in a ceremony in Shanghai on April 18th attended by leaders from both parties including Mr. Li Mao, Chairman of China Pingmei Shenma Group, and Mr. Michael Levi, Chairman of NILIT Group.
This model of collaboration showcases the mutual benefits of such alliances, including market access, regulatory navigation, and competitive advantage, emphasizing the market leadership of the NILIT team in China led by Shay Kastoriano, NILIT Asia GM, and Shenma as a strong local partner in China.
Furthermore, in response to the increasing demand for NILIT's high-end products and the commitment to innovation and sustainability, NILIT is also accelerating its plans to double the production capacity at NILIT’s existing production site located in Suzhou SIP, where Shenma Industrials will be a minority shareholder. This strategic move is aimed at supporting the growing global market demand for NILIT's products, ensuring customers’ needs for advanced and innovative and sustainable materials are met.
About NILIT
Celebrating 50 years of excellence, NILIT offers the broadest collection of premium sustainable Nylon 6.6 yarns designed to empower the apparel industry’s shift to a more sustainable position. With production plants in 4 continents (North America, South America, EMEA and ASIA), NILIT is dedicated to creating innovative and sustainable solutions to advance the textile industry.
NILIT launched industry-first SENSIL® ByNature made using bio-gas from reclaimed landfill waste. SENSIL® BioCare is enhanced with a special technology proven to help lessen the persistence of textile waste in sea water and in landfills. SENSIL® EcoCare, crafted with recycled Nylon, improves circularity and LCA. SENSIL® WaterCare with embedded color saves up to 100% of the water used in the traditional wet dyeing process. Plus, the complete SENSIL® portfolio of products is manufactured according to NILIT’s Total Product Sustainability criteria. These responsible yarns give designers the beautiful, environmentally considerate performance fabrics they need to create apparel collections that respond to consumer demands.
About Shenma
As a leading enterprise in the global Nylon 6.6 industrial yarn industry, Shenma has a strong Nylon 6.6 raw material base, providing a solid guarantee for its industrial yarn production. Therefore, its outstanding industrial yarn production capacity is well-known. It is a leading supplier in the global automotive industry, winning the trust of many leading automotive brands with its key components such as airbags and tire cords.
Through deep cooperation with these automotive brands, Shenma's reputation has been highlighted internationally. These partnerships demonstrate that Shenma is able to meet the strict quality and safety standards required by top manufacturers such as General Motors, Ford, Toyota, and Volkswagen. These partnership relationships not only highlight Shenma's commitment to the Nylon 6.6 supply chain, but also demonstrate Shenma's deep commitment to partners and customers.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240417236937/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom